Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapy
现代诱导治疗后复发或难治性FLT3突变型急性髓系白血病患者接受单药吉瑞替尼治疗的疗效
期刊:Blood Advances
影响因子:7.1
doi:10.1182/bloodadvances.2024014017
Othman, Jad; Hwang, Angela; Brodermann, Maximillian; Abdallah, Islam; McCloskey, Kayleigh; Gallipoli, Paolo; Clarke, Georgina; Dang, Raymond; Vidler, Jennifer; Krishnamurthy, Pramila; Basheer, Faisal; Latif, Anne-Louise; Palanicawandar, Renuka; Taylor, Tom; Khan, Asra; Campbell, Victoria; Hogan, Francesca; Kanellopoulos, Alex; Fleming, Kathryn; Collins, Angela; Dalley, Chris; Loke, Justin; Marshall, Scott; Taussig, David; Munisamy, Sreetharan; Loizou, Eleana; Yassin, Heba; Dennis, Mike; Zhao, Rui; Belsham, Edward; Murray, Duncan; Fowler, Nicole; O'Nions, Jenny; Khan, Anjum; Sellar, Rob; Dillon, Richard